|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
|
Fig. 6. siRNA targeting Jun inhibits neovascularisation in mice following hyperoxia-induced proliferative retinopathy. Postnatal day 6 (P6) C57BL/6 mice were exposed to hyperoxia (75% oxygen) for 4 days. P10 mice were returned to normoxia, and a bolus intravitreal injection of 20 µg of either Jun siRNA or siRNAscr was administered. Where indicated the siRNA was co-administered with 0.08 µg TGFß with or without 20 µM cis-9-octadecenoyl-N-hydroxylamide (cis-9-o-N-h). Mice were left at room oxygen for a further 7 days before P17 pup eyes were enucleated and fixed in 10% formalin in PBS. (A) Serial cross-sections of the eyes were stained with Haematoxylin and Eosin and blood vessels in the retina were quantified by light microscopy under 400x magnification and expressed as the mean ± s.e.m. Representative images at 100x magnification (upper panels). Jun siRNA inhibits hyperoxia-induced neovascularisation (lower panel). *P<0.05 by Student's t-test between groups as indicated. Immunoreactivity for (B) JUN, (C) MMP-2 or (D) Sp1 in retinal microvessels of mice treated intravitreally (20 µg) by single administration of Jun siRNA or siRNAscr or vehicle (no siRNA). Western blot analysis in C and D was performed with bEND-3 lysates as described in the Materials and Methods. Arrows in B-D indicate specific immunostaining (magnification, 1000x).
|
